This is a game changer. The likely start of a death spiral for Histogen. Coming from the VC world, it is quite common for bio start-ups to seek "surplus" funding right before phase results will be disseminated to public for two main reasons- capital raising prior to valuation erosion and capital sought for marketing/product launch which would have a difficult time getting raised with marginal results indicated. My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.
06-10-2013 10:22 AM
KO1
Quote:
Originally Posted by Phatalis
I don't think this is good advice. As Fin and Dut are dangerous. I'd never reccomend anyone take them.
I don't like the whole "I can handle fin" because even when people say they can you don't know how it's going to react with your endocrine system. Even if it seemingly doesn't do anything you won't know until it's too late.
I guess I just don't agree with pills that have such side effects. It's not worth it to me. Even if I responded well. I took fin for 3 weeks.. and was just too scared to continue.
My penis is worth more than my hair. Always will be. And I'm not even willing to give any % of a risk for it.
I don't know shit.
The boldest part is the only correct statement here.
This is the stupidest piece of advice a young man could ever get. This guy literally knows nothing about this drug, didn't get side effects himself, and now wants to discourage other people from taking the drug. Absolute dumbf**k.
If you're a young man losing his hair, you need to get on medications, and those can be fin, dut, or RU.
Go to www dot twinshairloss dot com. Then decide which twin you want to be.
06-10-2013 11:08 AM
clandestine
Quote:
Originally Posted by inkt2002
My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.
Your guess is worthless.
Less so, even.
06-10-2013 11:37 AM
UK_
Quote:
Originally Posted by inkt2002
This is a game changer. The likely start of a death spiral for Histogen. Coming from the VC world, it is quite common for bio start-ups to seek "surplus" funding right before phase results will be disseminated to public for two main reasons- capital raising prior to valuation erosion and capital sought for marketing/product launch which would have a difficult time getting raised with marginal results indicated. My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.
Riiight.. great.. and you are?
06-10-2013 11:49 AM
Thinning87
Quote:
Originally Posted by inkt2002
This is a game changer. The likely start of a death spiral for Histogen. Coming from the VC world, it is quite common for bio start-ups to seek "surplus" funding right before phase results will be disseminated to public for two main reasons- capital raising prior to valuation erosion and capital sought for marketing/product launch which would have a difficult time getting raised with marginal results indicated. My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.
these are not marginal results Mr. "Kleiner Perkins".... if you're going to come on an anonymous thread and act like you know something, at least do some research prior to giving a rating on a company in a market you know nothing about.
06-10-2013 12:20 PM
inkt2002
Quote:
Originally Posted by Thinning87
these are not marginal results Mr. "Kleiner Perkins".... if you're going to come on an anonymous thread and act like you know something, at least do some research prior to giving a rating on a company in a market you know nothing about.
Don't need to be an expert of an industry, rather an expert of the VC world to know whats going on. Whenever a company tries to jam through "surplus funding" right before phase results, you know a dark cloud is on the horizon. Try to raise as much capital at baseline valuation right before valuation takes a hit. Seen it way too many times before. They call it the death spiral.
Good luck.
